Intravitreal Hypertonic Buffer for XLRS Cyst Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for X-linked retinoschisis (XLRS) and intraretinal cysts, such as carbonic anhydrase inhibitors and gene therapy, have limited efficacy and are associated with systemic side effects or inflammation, and there is a need for effective long-term therapies to prevent or treat retinoschisis and reduce cyst formation.
Innovation Solution
Administration of a buffered saline solution, either hypertonic or isotonic, directly into the intravitreal space of the eye, optionally combined with topical or subconjunctival hypertonic solutions and intraocular pressure reduction techniques, to manage cyst severity and improve retinal function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy is administered intravitreally to treat XLRS, then retinal function is improved, but ocular inflammation occurs
Solution Approach 1:
The patent uses an aqueous composition (buffered saline solution) as an intermediary carrier to deliver gene therapy vectors intravitreally. This intermediary medium reduces direct irritation to the retina and surrounding tissues, thereby minimizing ocular inflammation while maintaining effective gene delivery to restore retinal function in XLRS patients.
Solution Approach 2:
The patent employs hypertonic buffered saline solution with specific osmolarity parameters to optimize gene therapy delivery. By controlling the physical-chemical parameters of the aqueous composition (tonicity, pH, buffer capacity), the patent enhances vector stability and retinal cell tolerance, reducing inflammatory responses while improving therapeutic efficacy.
2Manufacturing precision
If high dose gene therapy is administered to treat XLRS, then cyst reduction is improved, but ocular inflammation increases
Solution Approach 1:
The patent utilizes hypertonic buffered saline solution with optimized osmolarity parameters to deliver high doses of gene therapy vectors effectively. The controlled tonicity and buffer capacity of the aqueous composition enhance vector penetration and gene expression while minimizing retinal cell stress and inflammatory responses, achieving effective cyst reduction without excessive inflammation.
3Manufacturing precision
If current treatments (carbonic anhydrase inhibitors) are used to reduce intraretinal cysts, then cyst severity is reduced, but systemic side effects occur
Solution Approach 1:
The patent replaces systemic pharmacological treatment (carbonic anhydrase inhibitors) with localized intravitreal gene therapy delivery using aqueous composition. This substitution eliminates systemic circulation of drugs and their associated side effects, while achieving effective cyst reduction through direct action on retinal cells via the buffered saline solution carrier.
4Manufacturing precision
If rapid intraocular pressure reduction is performed to treat XLRS, then cyst formation is reduced, but procedural complexity increases
Solution Approach 1:
The patent combines intravitreal gene therapy delivery with intraocular pressure reduction techniques in a single integrated procedure using aqueous composition. By merging the therapeutic gene delivery function with the pressure management function, the patent achieves cyst formation reduction without requiring separate complex procedures, simplifying overall treatment while maintaining efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Hypertonic buffer administration reduces cyst severity, enhances cone-dominant electroretinography (ERG) amplitudes, and improves navigational vision in the light, while preserving cone cells and retinal function, outperforming isotonic buffer and untreated conditions.
Implementation Method 1
In all disclosed aspects, the aqueous composition comprises a buffered saline solution that may be a hypertonic buffered saline solution or an isotonic buffered saline solution
Data Source
AI summary
Disclosed are methods for treating X-linked retinoschisis (XLRS) in a subject in need thereof, for reducing intraretinal cysts, and/or preventing the formation of intraretinal cysts in a subject in need thereof.